Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yy003
- Development stage
- Phase 2
- Lead developer
- Claruvis Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Injection
01
Overview
YY003 is the world's first liquid formulation of recombinant Botulinum Toxin Type A (rBoNT/A), packaged in a pre-filled syringe. It is a SNAP25 modulator developed by Claruvis Pharmaceutical Co. The drug is designed primarily for the treatment of moderate to severe glabellar lines (frown lines). YY003 represents an innovation in the botulinum toxin market, offering a safer and more convenient option compared to traditional powder formulations that require reconstitution.
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on yy003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yy003.